Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Multiple myeloma patients undergoing chemotherapy: Which symptom clusters impact quality of life?

View through CrossRef
AbstractAims and ObjectivesTo identify symptom clusters and examine their association with health‐related quality of life.BackgroundMultiple myeloma patients undergoing chemotherapy suffer from disease symptoms and adverse effects during the course of the disease. However, single symptom management has little effect, and symptom management for these patients remains challenging. Symptom clusters open a new perspective and provide important clues for symptom management.DesignA cross‐sectional study.MethodParticipants were invited to complete the Chinese version of the Memorial Symptom Assessment Scale and Quality of Life Questionnaire‐core 30. Appropriate indicators were used for descriptive statistics. Principal component analysis was used to identify symptom clusters. Associations between symptom clusters and quality of life were examined with Pearson correlation coefficients, Pearson correlation matrix and multiple linear regression. This study was reported following the STROBE checklist.ResultsA total of 177 participants were recruited from seven hospitals in this study. We identified self‐image disorder, psychological, gastrointestinal, neurological, somatic and pain symptom clusters in multiple myeloma patients with chemotherapy. Approximately 97.65% of patients suffer from multiple symptom clusters. The pain, psychological and gastrointestinal symptom clusters have negatively influence on health‐related quality of life. The strongest association was found with the pain symptom cluster.ConclusionMost of multiple myeloma patients suffer from multiple symptom clusters. When improving the multiple myeloma patients' health‐related quality of life, the clinical staff should prioritise relieving the pain symptom cluster.Relevance to Clinical PracticeWhen multiple myeloma patients undergoing chemotherapy suffer from multiple symptom clusters, nurses should prioritise relieving the pain symptom cluster to improve their health‐related quality of life. When drawing up and providing interventions, nurses should focus on the correlation among symptoms rather than single symptom. By relieving one symptom in a given cluster, other symptoms within the same symptom cluster may also be relieved.
Title: Multiple myeloma patients undergoing chemotherapy: Which symptom clusters impact quality of life?
Description:
AbstractAims and ObjectivesTo identify symptom clusters and examine their association with health‐related quality of life.
BackgroundMultiple myeloma patients undergoing chemotherapy suffer from disease symptoms and adverse effects during the course of the disease.
However, single symptom management has little effect, and symptom management for these patients remains challenging.
Symptom clusters open a new perspective and provide important clues for symptom management.
DesignA cross‐sectional study.
MethodParticipants were invited to complete the Chinese version of the Memorial Symptom Assessment Scale and Quality of Life Questionnaire‐core 30.
Appropriate indicators were used for descriptive statistics.
Principal component analysis was used to identify symptom clusters.
Associations between symptom clusters and quality of life were examined with Pearson correlation coefficients, Pearson correlation matrix and multiple linear regression.
This study was reported following the STROBE checklist.
ResultsA total of 177 participants were recruited from seven hospitals in this study.
We identified self‐image disorder, psychological, gastrointestinal, neurological, somatic and pain symptom clusters in multiple myeloma patients with chemotherapy.
Approximately 97.
65% of patients suffer from multiple symptom clusters.
The pain, psychological and gastrointestinal symptom clusters have negatively influence on health‐related quality of life.
The strongest association was found with the pain symptom cluster.
ConclusionMost of multiple myeloma patients suffer from multiple symptom clusters.
When improving the multiple myeloma patients' health‐related quality of life, the clinical staff should prioritise relieving the pain symptom cluster.
Relevance to Clinical PracticeWhen multiple myeloma patients undergoing chemotherapy suffer from multiple symptom clusters, nurses should prioritise relieving the pain symptom cluster to improve their health‐related quality of life.
When drawing up and providing interventions, nurses should focus on the correlation among symptoms rather than single symptom.
By relieving one symptom in a given cluster, other symptoms within the same symptom cluster may also be relieved.

Related Results

Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Microwave Ablation with or Without Chemotherapy in Management of Non-Small Cell Lung Cancer: A Systematic Review
Abstract Introduction  Microwave ablation (MWA) has emerged as a minimally invasive treatment for patients with inoperable non-small cell lung cancer (NSCLC). However, whether it i...
Plasma Cell Disorders
Plasma Cell Disorders
Multiple myeloma represents 1.4% of all new patients with cancer and will result in an estimated 11,090 deaths in 2014. It is twice as common in black men as in white men and 2.5 t...
Plasma Cell Disorders
Plasma Cell Disorders
Multiple myeloma represents 1.4% of all new patients with cancer and will result in an estimated 11,090 deaths in 2014. It is twice as common in black men as in white men and 2.5 t...
Symptom clusters in patients receiving chemotherapy: A systematic review
Symptom clusters in patients receiving chemotherapy: A systematic review
Background and purposeSince 2001, symptom cluster research has grown considerably. However, because multiple methodological considerations remain, ongoing synthesis of the literatu...
Data from Functional B7.2 and B7-H2 Molecules on Myeloma Cells Are Associated with a Growth Advantage
Data from Functional B7.2 and B7-H2 Molecules on Myeloma Cells Are Associated with a Growth Advantage
<div>Abstract<p><b>Purpose:</b> B7 family molecules expressed on antigen-presenting cells stimulate or inhibit normal immune responses. The aim of this stud...
Data from Functional B7.2 and B7-H2 Molecules on Myeloma Cells Are Associated with a Growth Advantage
Data from Functional B7.2 and B7-H2 Molecules on Myeloma Cells Are Associated with a Growth Advantage
<div>Abstract<p><b>Purpose:</b> B7 family molecules expressed on antigen-presenting cells stimulate or inhibit normal immune responses. The aim of this stud...
MAF Protein Elicits Innate Resistance To Bortezomib In Multiple Myeloma
MAF Protein Elicits Innate Resistance To Bortezomib In Multiple Myeloma
Abstract Multiple myeloma (MM) is a malignancy of terminally differentiated clonal plasma cells displaying significant molecular heterogeneity with 7 subgroups defin...
Focal MIBI uptake is a better indicator of active myeloma than diffuse uptake
Focal MIBI uptake is a better indicator of active myeloma than diffuse uptake
Abstract:  Purpose: Technetium‐99m 2‐methoxyisobutylisonitrile (MIBI) imaging has been proposed as a front‐line investigation to detect bone disease both before and after the trea...

Back to Top